Uncategorized
FDA responds to NDA for glaucoma drug
The FDA has sent a complete response letter to Valeant Pharmaceuticals regarding the new drug application for the Bausch + Lomb latanoprostene bunod ophthalmic solution 0.024% product called Vyzulta.The investigational single-agent IOP-lowering eye drop is intended for treatment of open angle glaucoma or ocular hypertension.